Fosun Pharma Subsidiary Gains Approval for Ketoprofen Patch Clinical Trials
I'm PortAI, I can summarize articles.
Shanghai Fosun Pharmaceutical's subsidiary, Shanghai Zhaohui Pharmaceutical, has received approval from the National Medical Products Administration to begin Phase III clinical trials for a Ketoprofen Patch in China. This patch is intended for analgesic and anti-inflammatory uses. The approval is a significant step in the company's R&D efforts. The most recent analyst rating for Fosun Pharma's stock (HK:2196) is a Buy with a HK$35.30 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments